ClinicalTrials.govclosed
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
ClinicalTrials.gov study NCT07231575. IPD Sharing: NO. Countries: 0. Publications: 0.
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4
Topics
Dataset details
- Repository
- ClinicalTrials.gov
- Published
- February 11, 2026
- License
- IPD-NO
- DOI
- clinicaltrials.gov/NCT07231575
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.